CIA
ONC

Capital Impact Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Capital Impact Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,561
Closed -$4.31M – 136
2021
Q2 		$4.31M Buy
12,561
+7,110
+130% +$2.36M 1.39% 16
2021
Q1 		$1.9M Buy
+5,451
New +$1.81M 0.66% 66

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Capital Impact Advisors's ONC Position: Q3 2021 in Review

Capital Impact Advisors sold out of BeOne Medicines Ltd (ONC) in Q3 2021, closing a stake of 12,561 shares — an estimated $4.31M sold.

Capital Impact Advisors first reported a position in ONC in Q1 2021 and held it in 2 quarters. The position peaked at $4.31M in Q2 2021. 253 funds tracked by Wall St. Rank hold ONC as of Q3 2021.

  • Capital Impact Advisors reported no remaining BeOne Medicines Ltd position as of Q3 2021 after selling out during the quarter.
  • Capital Impact Advisors sold 12,561 BeOne Medicines Ltd shares in Q3 2021, an estimated $4.31M.
  • Capital Impact Advisors first reported a position in BeOne Medicines Ltd in Q1 2021 and held it in 2 quarters.
  • Capital Impact Advisors's BeOne Medicines Ltd position peaked at $4.31M in Q2 2021.
  • 253 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2021.

Based on Capital Impact Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.